Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : Israel to give Pfizer COVID-19 booster to 60 and over as Delta spreads

07/29/2021 | 05:32pm EDT

Israel will give people age 60 and over a Pfizer COVID-19 booster as the Delta variant spreads.

The inoculation process for people aged 60 and over will begin Sunday, The Wall Street Journal reported. It's based on early data suggesting vaccine protection against the Delta variant has waned.

Pfizer and BioNTech's COVID-19 vaccine is 39% effective in Israel amid the spread of the Delta variant, according to a report last week from the country's health ministry. Still, the report's data also showed that the two-dose vaccine was more than 40% effective against preventing symptomatic COVID-19, and 88% effective against COVID-19 hospitalization.

The third dose would be offered to the 60 and over group at least five months after their second shot, according to The Wall Street Journal and CNBC.

On Wednesday, Pfizer said it plans to seek clearance next month from U.S. regulators to distribute a booster shot.

A BioNTech- and Pfizer-funded study published Wednesday showed vaccine efficacy had dropped from 96% peak to nearly 84% after four months to six months. Pfizer CEO Albert Bourla said in a post-earnings conference call the same day that some people might need a third shot "a little earlier," than within 12 months to maintain high level of protection against the virus.

"We have seen also data from Israel that there is waning of immunity and that starts impacting what used to be what was 100% against hospitalization," Bourla told CNBC's "The Exchange" Wednesday. "Now, after the six-month period, is becoming low 90s and mid-to-high 80s."

Dr. Kate O'Brien, the World Health Organization's director of immunization, said in the CNBC report Wednesday the WHO doesn't recommend COVID-19 boosters "at this time," citing lack of data on their effectiveness.

U.S. and world health officials added they are looking at the Israeli research, but it was not peer-reviewed and lacks details.

Amid the rise in the Delta variant, Israel has also authorized Pfizer's COVID-19 vaccine for children between the ages of 5 and 11 with certain underlying health conditions that make them more at risk for severe illness or death from COVID-19, such as chronic lung disease.

In the United States, the Centers for Disease Control and Prevention recently updated guidance to recommend masks for everyone in public indoor settings -- including those who are fully vaccinated -- in counties which have substantial or high transmission rates.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source International Top News

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.45% 343.08 Delayed Quote.315.86%
PFIZER, INC. 0.18% 44.195 Delayed Quote.19.23%
All news about PFIZER, INC.
09:55aJOHNSON & JOHNSON : Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to Se..
06:23aEUROPEAN MIDDAY BRIEFING : Stocks Rebound But -3-
06:23aEUROPEAN MIDDAY BRIEFING : Stocks Rebound But -2-
04:00aPFIZER : Thai campaign to vaccinate schoolchildren makes progress
03:12aMARKETMIND : Losing the plot
09/20PFIZER : vaccine found to be safe, effective for children aged 5-11
09/20PFIZER : announces its vaccine is effective for kids 5-11
09/20Healthcare Shares Fall Amid Concerns About Delta Variant -- Healthcare Roundup
09/20Chevron, D.R. Horton fall; Pfizer, Brooks Automation rise
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 111 M - -
Net income 2021 18 438 M - -
Net Debt 2021 28 980 M - -
P/E ratio 2021 13,1x
Yield 2021 3,57%
Capitalization 248 B 248 B -
EV / Sales 2021 3,41x
EV / Sales 2022 4,03x
Nbr of Employees 78 500
Free-Float 59,3%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 20
Last Close Price 44,20 $
Average target price 45,08 $
Spread / Average Target 1,99%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.19.23%247 816
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
NOVO NORDISK A/S48.69%229 255
ABBVIE INC.-0.70%188 027